Trodelvy

  • April 12, 2021  

    FDA Grants Full Approval to Sacituzumab Govitecan for Triple-Negative Breast Cancer Bookmark

    George Lundberg, MD

    Recurrent triple-negative breast cancer is particularly difficult to treat. As reported by Cancer Network, the U.S. Food and Drug Administration (FDA) has now approved the drug sacituzumab govitecan (Trodelvy) for treating people with this disease, depending on their stage and treatment history.

    .